Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Frederiksburg, Denmark Clinical Trials

A listing of Frederiksburg, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (97) clinical trials

AZD5718 Phase IIa Study to Evaluate Efficacy Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries (Denmark, Finland and Sweden). Patients suitable for the study will be identified and screened for eligibility after being hospitalized for Acute Coronary Syndrome (ACS) (Visit ...

Phase

0.0 miles

Learn More »

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

The purpose of this phase 2 dose-ranging trial is to investigate the effects of FE 999302 on parameters influencing pregnancy rates in women undergoing Controlled Ovarian Stimulation (COS) with follitropin delta in a long gonadotropin releasing hormone (GnRH) agonist protocol. Furthermore, the study intends: To investigate the safety of FE ...

Phase

0.0 miles

Learn More »

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.

This is a randomized, double-blind, placebo controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and mid-range Ejection Fraction (HRmrEF). The study will be conducted at approximately 10 sites in 5 countries (USA, Sweden, Denmark, Finland, Netherlands). Patients suitable for the study will be ...

Phase

0.0 miles

Learn More »

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

Number of patients and target population: 144 patients with a diagnosis of alcohol dependence and 25 healthy participants (described later). The patients included in the trial will be treated for 26 weeks with once-weekly subcutaneous injection of Bydureon (exenatide) 2 mg or placebo. The medication will be provided as a ...

Phase

0.38 miles

Learn More »

Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis

This randomized double blind with double dummy technique phase 2a study will be run in 2-3 EU countries, most likely Sweden, Denmark and The Netherlands involving 5-6 sites. It is estimated that 80-100 patients have to be enrolled to ensure the randomization target of 40. The study population is patients ...

Phase

0.38 miles

Learn More »

Effect of High-dose Naloxone Following Third Molar Extraction

Naloxone is a combined mu-opioid-receptor (MOR) inverse agonist and antagonist drug, which dose-dependently demonstrates hypoalgesic and hyperalgesic properties. Systemically administrated naloxone (3.0-10.0 mg/kg) and naltrexone (0.3-3.0 mg/kg) have been used in rodents to study the role of endogenous opioids on central processing of pain. It has been hypothesized that the ...

Phase

1.73 miles

Learn More »

The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses

BACKGROUND Neuromuscular diseases affect more than 5% of the population in Western countries. Some of the more rare neuromuscular disorders are patients with metabolic myopathies, which are hereditary disorders caused by enzymatic defects of intermediary metabolism. The disorders are generally subdivided in two major groups affecting either carbohydrate metabolism (the ...

Phase

1.73 miles

Learn More »

Aspirin in Colorectal Cancer Liver Metastases

The ASAC trial is a Scandinavian, multi-center, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose acetylsalicylic acid (ASA) can improve disease free survival in patients treated with resection for colorectal cancer liver metastases (CRCLM). Several studies have shown beneficial effect of ASA on primary prevention of CRC ...

Phase

2.14 miles

Learn More »

PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105

68Ga-NOTA-AE105 is a radioligand targeting urokinase plasminogen activator receptor (uPAR), which is a promising imaging biomarker of tumor aggressiveness. A total of 120 NET patients will be subjected to a uPAR-PET/CT scan. Follow-up will be performed (from the time of the angiogenesis PET/ CT) at 6 months for disease specific ...

Phase

2.14 miles

Learn More »

uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness

Prostate cancer is one of the most frequent types of cancer in men. The characteristics of the disease varies significantly among patients where some have an indolent type of cancer, from which they will never experience symptoms while others have highly aggressive malignant disease that requires prompt therapeutic action. Treatment ...

Phase

2.14 miles

Learn More »